Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Transcriptional repressor which preferentially binds to the GC-rich consensus sequence (5'-AGCCCCCGGCG-3') and may regulate expression of TNF, EGFR and PDGFA.
Showing 10 out of 29 products:
Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling pathway.
High GCF2 (show GCFC2 Antibodies) expression is associated with hepatoma.
Higher baseline LRRFIP1 expression in human glioblastoma multiforme tissue (n=60) is associated with better prognosis upon later treatment with teniposide.
Data indicate that LRRFIP1 knockdown increased resting TNF (show TNF Antibodies) mRNA level altered the ncRNA abundance at the LRRFIP1 binding region.
The FLI (show FLII Antibodies)-interacting domain of LRRFIP1 forms a classic parallel, homodimeric coiled coil with 10 heptad repeats and 22 helical turns.
GCF2/LRRFIP1 plays an important role in colorectal cancer metastasis by regulating RhoA (show RHOA Antibodies)-induced cell adhesion.
LRRFIP1 is phosphorylated in response to immunologic stimuli and it is directed to lysosomal structures.
An association study of 6 of the 63 genes in 4235 cases and 6379 controls showed a putative association with myocardial infarction for COMMD7 (COMM domain-containing protein 7 (show COMMD7 Antibodies)) and a major deviation from the null hypo thesis for LRRFIP1.
GCF2/LRRFIP1 appears to act as a repressor and occupies the -308 site in cells that do not make TNF-alpha (show TNF Antibodies).
Immediately following lipopolysaccharide stimulation, both LRRFIP2 (show LRRFIP2 Antibodies) and Flap-1/LRRFIP1 compete with Fliih (show FLII Antibodies) for interacting with MyD88 (show MYD88 Antibodies) to activate the signaling.
TRIP as a negative regulator in TLR3 (show TLR3 Antibodies)/4- and RIG-I (show DDX58 Antibodies)-triggered antiviral responses and suggested TRIP as a potential target for the intervention of diseases with uncontrolled IFN-beta (show IFNB1 Antibodies) production.
Transcriptional repressor which preferentially binds to the GC-rich consensus sequence (5'-AGCCCCCGGCG-3') and may regulate expression of TNF, EGFR and PDGFA. May control smooth muscle cells proliferation following artery injury through PDGFA repression. May also bind double-stranded RNA. Positively regulates Toll-like receptor (TLR) signaling in response to agonist probably by competing with the negative FLII regulator for MYD88-binding.
GC-binding factor 2
, LRR FLII-interacting protein 1
, NEDD8-conjugating enzyme
, TAR RNA-interacting protein
, leucine-rich repeat flightless-interacting protein 1